Correlative analyses ofRETand RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions

(2015) S. Fujita-Sato et al.   CANCER RESEARCH

Vandetanib for the Treatment of Medullary Thyroid Carcinoma

(2014) Maryann R. Cooper et al.   ANNALS OF PHARMACOTHERAPY

A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H

(2014) Keith C. Bible et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans

(2014) Iván Plaza-Menacho et al.   MOLECULAR CELL

High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas

(2014) Michele Simbolo et al.   VIRCHOWS ARCHIV

Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer

(2013) David Viola et al.   Future Oncology

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) F. Pacini et al.   ANNALS OF ONCOLOGY

SomaticRASMutations Occur in a Large Proportion of SporadicRET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified Exon

(2012) A. Boichard et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations inRETandRAS

(2012) Nishant Agrawal et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series

(2012) Raffaele Ciampi et al.   THYROID

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

(2011) Merina Ahmed et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

High Prevalence ofRASMutations inRET-Negative Sporadic Medullary Thyroid Carcinomas

(2011) Margarida M. Moura et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma

(2010) Clarissa Capp et al.   THYROID

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas

(2009) M M Moura et al.   BRITISH JOURNAL OF CANCER

Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets

(2009) Aniello Cerrato et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

(2009) Richard T. Kloos (Chair) et al.   THYROID

Medullary Thyroid Carcinoma: Targeted Therapies and Future Directions

(2009) Scott N. Pinchot et al.   Journal of Oncology

Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study

(2007) Rossella Elisei et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM